Conference Agenda

Conference Agenda

DxPx EU 2026

Day 1: February 5, 2026

10:00 - 12:00TBD

DxPx Capital & Croissants

Joins us at DxPx Investors-only breakfast. Free to join. No PowerPoints, no status pitches – just conversations that matter. New or lesser know VCs can contact us for a reverse pitch slot.

13:00 - 13:10

Welcome & Introduction

13:10 - 13:35

Keynote: “The Market Pulse – Global Growth & Investment Trends in Diagnostics & Life Science Tools”

Global and regional growth trends in Dx & Biotools
Shifts in M&A and PE appetite post-2024
R&D and digital transformation benchmarks
Key valuation and capital flow data

13:35 - 14:05

Strategy Panel: “Competing in a Converging Market – Innovation, Partnerships, and Value Creation”

How shifting regulation, reimbursement, and digitalization impact competitive advantage
Building transatlantic partnerships and scaling innovations
What makes an attractive target or partner in today’s environment

14:05 - 14:55

Executive Roundtable: “Scaling Science – Growth Strategies from Industry Leaders”

How global leaders evaluate partnerships and acquisitions
Outlook for innovation sourcing: from venture to M&A integration
Capital efficiency, localization, and sustainability in scaling operations
Where PE and industry can collaborate to accelerate growth

14:55 - 15:00

Closing Remarks & Networking Invitation

16:00 - 18:00Andaz Munich Schwabinger Tor

DxPx Market Pulse: Global Life Science & Biotools Outlook: Market Dynamics, Deals, and Growth Hotspot

Modeled after ADLM’s renowned International Market Briefing, this one-hour session offers a deep dive into global trends shaping diagnostics, life science tools, and biotools. With insights from XXX, XXX, and XXX, participants will gain data-driven perspectives on market growth, competitive dynamics, and investment activity across key regions. Co-hosted by ADLM, this session will serve as a strategic briefing for investors, startups, and corporates navigating the evolving global landscape.

19:00 - 21:30Bodega Dali

Growth for Capital Dinner

Bodega Dali
Tengstraße 6, 80798 München

20:00 - 23:00Leonardo Royal Munich – Hotel Bar

Network Reception

Join us for cocktails, finger foods and plenty of networking to open the DxPx Conference.

Day 2: February 6, 2026

Plenary: Biomarker

Keynote

08:30 - 09:00

Details coming soon.

Plenary: Helix

Keynote

08:30 - 09:00

Details coming soon.

09:00 - 17:00Partnering & Exhibition Area

One-on-One Partnering and Exhibition

Diagnostics: Company presentations

Company presentation slots

Precision Medicine: Company presentations

Company presentation slots

Digital Health: Company presentations
Biotools: Company presentations
12:30 - 13:30Lobby

Lunch

Date & Location:

Reception: Thursday, February 5th, 2026
Partnering Day & 42PLUS1: February 6th, 2026

Leonardo Royal Munich
Moosacher Straße 90 | 80809 München | Germany

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.

Experience

Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.

Experience

John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.

Experience

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.

Experience

FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Experience

Participate in the DxPx Pitch competition as startup or virtual juror and join DxPx Conference for 499 EUR.